cyclosporine / Generic mfg. - LARVOL DELTA

Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin. (PubMed, N Engl J Med) - P3 | "The combination of post-transplantation cyclophosphamide and a calcineurin inhibitor led to longer GVHD-free, relapse-free survival than standard prophylaxis after transplantation from a matched related donor with either reduced-intensity or myeloablative conditioning in patients with blood cancers. (Funded by the Australian Government Medical Research Future Fund and others; ALLG BM12 CAST Australian-New Zealand Clinical Trials Registry number, ACTRN12618000505202.)."

Journal • Acute Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Oncology • Transplantation

Idiopathic Pure Red Cell Aplasia Presenting With Chronic Macrocytosis and Early Relapse: A Case Report and Literature Review. (PubMed, Cureus) - "Treatment with concurrent cyclosporine and prednisone resulted in remission within three months. Cyclosporine-based regimens were associated with the highest remission rates, while relapse and macrocytosis were infrequently reported. This case highlights macrocytosis as a potential atypical presenting feature of IPRCA and underscores the importance of recognizing relapse and ensuring long-term follow-up."

Journal • Aplastic Anemia • Hematological Disorders

Successful Management of Relapsed Severe Immune Thrombocytopenia Using Avatrombopag: A Case Report. (PubMed, Case Rep Hematol) - "We report the case of a 37-year-old woman with relapsed severe ITP, unresponsive to corticosteroids, IVIG, rituximab, romiplostim, eltrombopag, vincristine, cyclosporine, and splenectomy. This case demonstrates the efficacy of avatrombopag in a patient unresponsive to multiple prior therapies, including other TPO-RAs and splenectomy. Further studies are warranted to determine optimal treatment sequencing and long-term outcomes for patients in this challenging subgroup."

Journal • Cardiovascular • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura

Incidence of Pure Red Cell Aplasia Post Allogenic Hematopoietic Stem Cell Transplant in Patients with Major ABO Mismatch in Post Cytoxan Era — a Single Center Analysis (TCT-ASTCT-CIBMTR 2026) - "Presence of recipient anti-A hemagglutinin, use of reduced-intensity conditioning (RIC) regimens, cyclosporine use, sibling donors, and absence of acute graft versus host disease (aGVHD) are risk factors for PRCA...However, the impact of PtCy-based ppx on the risk of PRCA among major ABO mismatched alloHCT recipients relative to traditional tacrolimus (Tac)/methotrexate (MTX)-based ppx is not known...6-month CI of PRCA was higher following RIC with fludarabine/busulfan (14%, 95%CL: 6.7, 23) as compared to other regimens (p=0.019)...4. Evaluate factors affecting PRCA incidence."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Transplantation

Faster, Higher, Stronger - Together. Twenty Years Data on Safety and Efficacy of Tacrolimus in Children (TCT-ASTCT-CIBMTR 2026) - "Children less than 1 year and who received a haploidentical TCR alpha beta depletion HSCT were excluded from the study and received upfront cyclosporine...Overall tarcolimus well-tolerated with major toxicities (renal dysfunction, hypertension, PRES) more common in children <3 years, Fanconi anemia, and sickle cell disease 3. Sublingual tacrolimus ensures therapeutic trough levels in most pediatric HSCT patients, offering a simple alternative during mucositis"

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Cardiovascular • Chronic Graft versus Host Disease • Diabetes • Genetic Disorders • Graft versus Host Disease • Hypertension • Immunology • Metabolic Disorders • Movement Disorders • Mucositis • Nephrology • Pancreatitis • Sickle Cell Disease

Post-Transplant Cyclophosphamide GVHD Prophylaxis Has a Unique Vascular Toxicity Compared to Abatacept Containing Regimens. (TCT-ASTCT-CIBMTR 2026) - "Introduction: Post-transplant cyclophosphamide (PTCy) reduces acute graft versus host disease (GVHD) but alters vascular biomarkers, with an increase in angiopoietin -2 at day+28 post hematopoietic stem cell transplant (HSCT) in adult transplant recipients (Newell et al, Blood VTH 2024)... Patients were categorized into four GVHD prophylaxis cohorts 1) Cyclosporine (CSA) and mycophenolate mofetil (MMF), 2) CSA, MMF and abatacept, 3) post-transplant cyclophosphamide (PTCy) and 4) T cell depleted (TCD) graft... Vascular biomarkers of endothelial injury and clinical TA-TMA were higher in the PTCy group compared to the patients that received abatacept as part of their GVHD prophylaxis. The incidence of aGVHD was higher in the PTCy group. Further studies of the use of abatacept as part of GVHD prophylaxis regimens in children and specific vascular biomarkers should be studied further."

Post-transplantation • Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Immunology • Transplantation • Transplantation Associated Thrombotic Microangiopathy • FLT1 • ST2

Immune-Effector Cell-Associated Enteritis/Colitis (IEC-EC) after Ciltacabtagene Autoleucel (cilta-cel) in Multiple Myeloma (MM): Updated Clinicopathologic Data and Management (TCT-ASTCT-CIBMTR 2026) - "Treatments for mild cases included supportive care, mesalamine, and corticosteroids; treatments for severe cases included infliximab, vedolizumab, cyclosporine, high-dose cyclophosphamide, and ruxolitinib. IEC-EC is a heterogenous condition with a wide variety of clinical presentations. Severe cases are associated with a high risk of infection and mortality; however, we report for the first time that milder cases responsive to brief corticosteroid courses may also occur. Optimal diagnostic strategies include prompt endoscopic evaluation evaluating both small and large bowel, targeted biopsies regardless of endoscopic appearance, and rule-out of infectious or lymphoproliferative processes."

Clinical • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Immunology • Infectious Disease • Multiple Myeloma • CD4 • CD8

Initial Experience with Generic Letermovir [Anvimo] in Preventing Cytomegalovirus Reactivation in Hematopoietic Stem Cell Transplant Recipients Who Are at a High Risk of Infection. (TCT-ASTCT-CIBMTR 2026) - "Anvimo was started following engraftment at a dose of 240 mg [with cyclosporine] or 480 mg till Day 100...Majority of patients with reactivation received ganciclovir as pre-emptive therapy and cleared the viremia... Generic Letermovir [Anvimo] in useful in reducing the incidence of CMV reactivation especially in haplo-identical transplants. More long-term data is needed to look at secondary reactivation and survival. 1."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Infectious Disease • Transplantation

Hematopoietic Stem Cell Transplant for Aplastic Anemia Is Feasible in a Tier-2 City : An Experience from an Eastern State of India. (TCT-ASTCT-CIBMTR 2026) - "Patients received a conditioning regimen comprising Fludarabine, Cyclophosphamide, and Anti- Thymocyte Globulin (ATG)...GVHD prophylaxis included Cyclosporine and Methotrexate...Graft failure: 3 patients (17%) experienced primary graft failure — 1 underwent a successful second BMT, 1 is in partial remission on Cyclosporine and Eltrombopag, and 1 died... Our data suggest that allogeneic HSCT for Aplastic Anemia is feasible and effective in a tier-2 city setting, with an acceptable toxicity profile and a remission rate of 70%. Larger studies with extended follow-up are needed to better understand long-term outcomes and disease dynamics. 1) Understanding Indication of HSCT in Aplastic Anemia 2 ) Review conditioning Regimens used in HSCT for Aplastic Anemia 3) Bone marrow transplant offers better outcome for Aplastic patients."

Acute Graft versus Host Disease • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Septic Shock • Transplantation

Outcomes of Allogenic Hematopoietic Stem Cell Transplant in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Retrospective Multicenter Analysis on Behalf of Pakistan Blood and Marrow Transplant (PBMT) Group (TCT-ASTCT-CIBMTR 2026) - "Graft versus host disease (GVHD) prophylaxis was with Antithymocyte globulin (ATG) + Cyclosporin (CSA) in patients receiving NMA conditioning or ATG + CSA + short term Methotrexate (MTX) in those receiving MAC. In resource-constrained environments lacking access to complement inhibitors, allogeneic HSCT remains a curative and feasible treatment modality for PNH, with promising survival rates and acceptable treatment-related toxicity. 1- To evaluate the survival outcomes in patients with Paroxysmal Nocturnal Hemoglobinuria, undergoing HSCT 2- To identify HSCT related complications including Infections, GVHD and TRM 3- To assess the efficacy and safety of HSCT for Paroxysmal Nocturnal Hemoglobinuria in resources constrained settings, having little or no access to complement Inhibitor therapy."

Retrospective data • Acute Graft versus Host Disease • Aplastic Anemia • Bone Marrow Transplantation • Cardiovascular • Chronic Graft versus Host Disease • Complement-mediated Rare Disorders • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases • Thrombosis • Transplantation

Outcomes of Patients with Acquired Aplastic Anemia Receiving Matched Related Donor Transplant in a Low Middle Income Country: A Multicenter Study on Behalf of Pakistan Blood and Marrow Transplant Group (TCT-ASTCT-CIBMTR 2026) - "Graft versus host disease prophylaxis used was Cyclosporine (CsA) alone in 39.9% and CsA+ methotrexate (MTX) in 47.7% patients. Fludarabine (120-150mg/m2), cyclophosphamide(Cy) 120- 160 mg/kg, anti-thymocyte globulin 20 mg/kg was used as conditioning in 52.1% (n-373) patients, Cy 200 mg/kg-ATG 20 mg/kg in 20.4% (n=146) patients...OS(75.5%) was significantly better for patients receiving BMH+PBSC as graft source as compared to BMH alone(70.4%) and PBSC alone (64.8%), p=.01.Multivariate analysis showed higher mortality for patients not receiving ATG (HR :1.71; 95% CI: 0.95-3.06, P= 0.01) , RCC transfusion >30 units (HR,1.34; 95%CI 0.71-2.54, P=0.003) and use of CsA + mycophenolate mofetil as GVHD prophylaxis (HR:2.47; 95%CI:1.46- 4.18, p-0.003)... Allogeneic HSCT remains the treatment of choice for severe and very severe AA in LMICs. Survival outcomes are lower than developed countries and can be improved by better infection control and adopting optimized conditioning..."

Clinical • Acute Graft versus Host Disease • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Renal Cell Carcinoma • Septic Shock • Transplantation

Post-Transplantation Cyclophosphamide after HLA-Matched Growth Factor-Mobilized Blood Cell Transplantation with High Dose Myeloablative Conditioning (TCT-ASTCT-CIBMTR 2026) - "GVHD prophylaxis was with PTCy plus single-agent cyclosporine (CSP) (N=120) or with a calcineurin inhibitor (CNI; CSP or tacrolimus) plus methotrexate (MTX) (N=356). Patients receiving PTCy were prepared with either ≥12 Gy TBI (N=168) or high dose busulfan plus fludarabine (N=308), whereas patients receiving CNI/MTX received their Cy before day 0 (TBI/Cy or Bu/Cy)... For patients eligible for high-dose conditioning who have HLA-matched donors, post-grafting immunosuppression with PTCy/CSP is associated with superior long-term GRFS compared to the previous standard with CNI/MTX. The superior GRFS observed with the PTCy-based regimen was mainly driven by lower rates of cGVHD and severe acute GVHD, and there was no indication that PTCy increased the toxicity of the procedure. To understand..."

Post-transplantation • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Transplantation

Single-Unit Cord Blood Transplantation Achieves Superior Engraftment and Less Cgvhd Compared to Double-Unit Transplantation (TCT-ASTCT-CIBMTR 2026) - " Between April 2006 and February 2025, 315 patients with malignant diseases underwent first sCBT (n=94) or dCBT (n=221) using Flu/Cy/TBI (n=182), Flu/Cy/Thiotepa/TBI (n=47), or Treo/Flu/TBI (n=86) conditioning regimens. GVHD prophylaxis included mycophenolate mofetil and cyclosporine in all cases... sCBT was not inferior to dCBT and was associated with excellent clinical outcomes, including faster hematopoietic recovery and a lower risk of chronic GVHD. These findings support the use of sCBT when adequate cell doses are available, substantially reducing the cost of CBT without compromising efficacy. To evaluate characteristics of cord blood units used in transplants completed at FHCC between April 2006-February 2025 Compare the outcomes of single versus double cord blood transplant for hematologic malignancies Understand efficacy and feasibility of cord blood transplant practices"

Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Transplantation • CD34 • HLA-DRB1

Posttransplant Cyclophosphamide Allows Allogeneic Stem-Cell Transplantation across Donor Types for Nonmalignant Hematologic Diseases. (TCT-ASTCT-CIBMTR 2026) - "Graft- versus-host disease (GVHD) prophylaxis was CNI/MTX or PTCY, mycophenolate mofetil, and tacrolimus (PTCY cohort)... The CNI/MTX cohort (N=14) with SAA had fludarabine (FLU)/CY/ATG (thymoglobulin)/total body irradiation (TBI) (N=11) or CY/ATG (N=3) alloSCT...A SAA patient relapsed 2 years after immunosuppressive therapy (horse ATG, cyclosporine, eltrombopag) and had haploidentical BM alloSCT 804 days from diagnosis... Uniform conditioning with FLU/CY/ATG/TBI 4Gy alloSCT and PTCY GVHD prophylaxis is effective in adults with SAA or DBA across donor types (MRD, syngeneic, MUD, haploidentical) and should be prospectively compared with historical regimens. 1. To compare posttransplant cyclophosphamide-based regimens with historical regimens with calcineurin inhibitor/methotrexate for allogeneic stem-cell transplant in nonmalignant hematologic disorders."

Post-transplantation • Aplastic Anemia • Genetic Disorders • Graft versus Host Disease • Hematological Malignancies • Immunology • Transplantation

Antithymocyte Globulin Free Non-Myeloablative Conditioning Regimen for Older Patients with Aplastic Anemia (TCT-ASTCT-CIBMTR 2026) - P2 | "GVHD prophylaxis was cyclosporine or tacrolimus and MMF for 4 patients with the addition of sirolimus for the 5 patients transplanted between 2017-2021. The ATG-free conditioning regimen, fludarabine plus 2-4 Gy TBI, with a calcineurin inhibitor plus MMF (with or without sirolimus) for GVHD prophylaxis, is well tolerated in older adults and is sufficient for engraftment and cure of AA with encouraging OS, especially considering that the majority of patients were previously treated with IST and received PBSC from unrelated donors. A study is currently ongoing at our center (NCT06752694) to add peri-HCT Ruxolitinib to the current regimen to better prevent acute and chronic GVHD. 1."

Clinical • Acute Graft versus Host Disease • Anemia • Aplastic Anemia • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Myelodysplastic Syndrome • CD33

Treosulfan – Based Conditioning in Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT): A Single Center, 20-Year Experience. (TCT-ASTCT-CIBMTR 2026) - " We have used the combination of fludarabine and Treosulfan as the conditioning regimen for allogeneic HSCT in patients (pts) with various hematological malignancies, considered eligible for low to intermediate transplant conditioning intensity, over the last 20 years...GVHD prophylaxis included cyclosporine and methotrexate or mycophenolate... Treosulfan- based conditioning can allow promising long-term OS in pts with a variety of hematological malignancies. It is associated with potent anti-malignancy effect combined with relatively low NRM and GVHD rates. Long-term outcome analysis (up to 20 years) shows significant cure rate, although late events (beyond 2 years) are significant, underscoring the importance of long-term monitoring in assessing HSCT outcomes."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Transplantation

Impact of Severe Infections on Non-Relapse Mortality after Allogeneic HCT: A Post-Hoc Analysis of a Randomized Phase II Study Comparing Post-Transplantation Cyclophosphamide (PTCy) and Non-Ptcy-Based GVHD Prophylaxis (TCT-ASTCT-CIBMTR 2026) - P2 | "Background: A prior randomized phase II trial (NCT03246906) of graft-vs-host disease (GVHD) prophylaxis with sirolimus and cyclosporine combined with either post-transplant cyclophosphamide (PTCy) or mycophenolate mofetil (non-PTCy) showed superior GVHD-free relapse-free survival but delayed engraftment and higher rates of grade ≥3 infections with PTCy (Ueda Oshima, JCO 2025). Severe infections were associated with markedly higher NRM in PTCy but not in non-PTCy patients. This differential effect was largely driven by bacterial and fungal infections and may be due to compromised immune reconstitution, delayed engraftment, and increased susceptibility to organ dysfunction after PTCy. Our findings suggest a need to optimize targeted infection surveillance, prevention and supportive care in PTCy-treated patients."

Clinical • P2 data • Post-transplantation • Retrospective data • Graft versus Host Disease • Immunology • Infectious Disease • Transplantation

Outcomes of Treosulfan, Thiotepa and Fludarabine Conditioning in Matched Sibling Donor Vs. Haploidentical Related Donor Hematopoietic Stem Cell Transplant for Children and Young Adults with Sickle Cell Disease (TCT-ASTCT-CIBMTR 2026) - "Rabbit ATG (thymoglobulin) 2.5 mg/kg on day-2 and day-1 was given to those undergoing MSD and on day -6 and day-5 to those undergoing Haploidentical HSCT...Graft versus host disease (GVHD) prophylaxis was cyclosporine and Methotrexate for MSD HSCT and PTCy 50 mg/kg on day+3 and 4 along with MMF & tacrolimus for Haploidentical Donor HSCT. All children undergoing haploidentical HSCT with anti-Human leukocyte antigen (HLA) antibodies >3000 MFI were given pre transplant immune suppression (PTIS) for 6 weeks (Cyclophosphamide 1000 mg/m2 on day 1 and day22, Rituximab 100 mg/m2 on day8,15,29,36 and MMF and hydroxyurea)...Conclusion– Outcomes of TTF conditioning is superior in children and young adults undergoing MSD HSCT vs haploidentical HSCT with PTCy for sickle cell disease. Treosulfan, Thiotepa and fludarbine (TTF) based conditioning is effective in sickle cell disease patients udergoing HSCT Outcomes are superior for patients undergoing matched sibling donor HSCT..."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • CNS Disorders • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Immunology • Sickle Cell Disease • Transplantation

A Cost-Conscious, and Highly Successful Start-up Strategy for Hematopoietic Cell Transplantation in Low- and Middle-Income Countries Supported By DKMS (TCT-ASTCT-CIBMTR 2026) - "The protocol consisted of pre- transplant immunosuppression with fludarabine/dexamethasone followed one month later by fludarabine, busulfan and cyclophosphamide. G-CSF-primed bone marrow was used as stem cell source followed by cyclosporine/methotrexate prophylaxis... A total of 141 consecutive first bone marrow transplants (BMTs) were included in the analysis, consisting 128 patients (median age: 6.04 years; IQR: 4.1–9.1 years) from established centres and 13 patients (median age: 5.12 years; IQR: 4.1–6.1 years) from startup centres. Of the 128 patients treated at established centres, 122 were diagnosed with thalassemia major and 6 with sickle cell disease (SCD). All 13 patients at the startup centres had thalassemia major with liver size ≤3 cm below the costal margin at transplantation."

Beta-Thalassemia • Bone Marrow Transplantation • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Sickle Cell Disease • Transplantation

MYELOABLATIVE CONDITIONING WITH FRACTIONATED BUSULFAN AND CHIDAMIDE IN HIGH-RISK AML/MDS PATIENTS WITH RESIDUAL OR ACTIVE DISEASE PRIOR TO TRANSPLANT (EBMT 2026) - "Fludarabine and cytarabine were given from day -7 to -3, and chidamide (20 mg twice weekly) from day -15 to +2...Acute GVHD prophylaxis consisted of cyclophosphamide (days +3, +4), cyclosporine (from day +5), and mycophenolate mofetil for haploidentical transplants (day +5 to +35)... The combined fractionated busulfan and chidamide regimen is feasible, well-tolerated, and facilitates rapid remission with promising survival in high-risk AML/MDS patients with inadequate pre-transplant disease control, supporting its further evaluation."

Clinical • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Immunology • Infectious Disease • Myelodysplastic Syndrome • Pneumonia • Respiratory Diseases • Septic Shock • Transplantation

ALLOGENEIC TRANSPLANTATION AFTER FAILURE OF CAR-T CELLS AND EXPOSURE TO BISPECIFIC ANTIBODIES: FEASIBILITY, SAFETY AND SURVIVAL OUTCOMES (EBMT 2026) - "Prior CAR-T product were axicabtagene ciloleucel (n=8) or tisagenlecleucel (n=11); BsAb was glofitamab (n=18) or epcoritamab (n=1)...Uncommon toxicities included one steroid-responsive hemolytic anemia, one anti-GM2-ganglioside IgM-positive acute demyelinating polyneuropathy diagnosed 10 months after alloSCT, successfully managed with intravenous immunoglobulins with complete recovery, and one case of iatrogenic encephalopathy on a likely microangiopathic basis, possibly related to cyclosporine... AlloSCT consolidation after CAR-T cells and BsAb exposure is feasible in selected, fit and responding patients, providing durable disease control with acceptable toxicity. Despite heavy pre-treatment, no unexpected safety signals emerged, with relatively low GvHD rates across donor type, and limited transplant-related mortality. In conclusion, alloSCT consolidation should be offered to all eligible patients failing both T-cell redirecting strategies, and carefully evaluated..."

CAR T-Cell Therapy • Clinical • Acute Graft versus Host Disease • B Cell Lymphoma • Chronic Graft versus Host Disease • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Transplantation

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (clinicaltrials.gov) - P4 | N=10 | Not yet recruiting | Sponsor: University of California, San Francisco

New P4 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Psoriasis

HAPLOIDENTICAL VERSUS FULLY MATCHED RELATED DONOR STEM CELL TRANSPLANTATION IN PEDIATRIC AND YOUNG ADULTS WITH SEVERE APLASTIC ANEMIA: A SINGLE-CENTER EXPERIENCE FROM A RESOURCE-LIMITED SETTING (EBMT 2026) - "The single patient previously treated with rabbit ATG and cyclosporine developed posterior reversible encephalopathy syndrome (PRES), which resolved with supportive management and treatment adjustment.Sixteen transplants were performed in 15 patients (median age 7 years; range 3–20; males n=8)...Conditioning consisted of fludarabine (150 mg/m²), cyclophosphamide (29 mg/kg), antithymocyte globulin (2.5 mg/kg), and TBI (4 Gy) for haploidentical transplants, while fully matched related donor transplants received reduced-dose TBI. GVHD prophylaxis included a calcineurin inhibitor and methotrexate for matched related donors, and post-transplant cyclophosphamide with a calcineurin inhibitor and mycophenolate mofetil for haploidentical donors...Day +30 chimerism (n=12) demonstrated high donor fractions (median ~99%).Acute GVHD occurred in two haploidentical recipients: one with hyperacute steroid-refractory gastrointestinal GVHD successfully treated with etanercept and..."

Clinical • Acute Graft versus Host Disease • Anemia • Aplastic Anemia • Chronic Graft versus Host Disease • CNS Disorders • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Pediatrics • Transplantation • DDX41

A Rising Cluster of Erythropoietin-Associated Pure Red Cell Aplasia and Subsequent Response to Roxadustat: A Case Series. (PubMed, Nephrology (Carlton)) - "We describe 14 cases of Epoetin-alfa associated PRCA which have resulted in significant morbidity...Heterogeneous immunosuppression regimens were used, predominantly with either monotherapy prednisone or ciclosporin...Our cluster of cases highlights the need for strong suspicion of acquired PRCA in patients treated with erythropoietin products who present with refractory anaemia. HIF stabilisers such as Roxadustat, which have otherwise not been licensed in New Zealand, seem to be beneficial in these cases, possibly minimising the need for heavy immunosuppression."

Journal • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

Standardising the diagnosis and management of atopic dermatitis in India: A consensus statement by the modified Delphi method by IADVL Special Interest Group of Pediatric Dermatology (STAND AD). (PubMed, Indian J Dermatol Venereol Leprol) - "For systemic therapy, cyclosporine remains first-line for moderate-to-severe AD, with conditional recommendations for methotrexate, mycophenolate, and JAK inhibitors such as abrocitinib. Emerging therapies like topical tofacitinib and crisaborole were discussed with caution due to limited Indian data. Limitation Although several new therapies-such as abrocitinib and dupilumab-have been approved for pediatric atopic dermatitis, consensus among Delphi panelists remains limited...It addresses previously unmet needs in adult AD. This consensus is expected to enhance clinical outcomes and standardise AD management nationally."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Pediatrics